EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Lenalidomide in combination with rituximab, dexamethasone, high-dose ARA-C and cisplatinum as salvage therapy in refractory or relapsed aggressive B-cell non-hodgkin-lymphoma - an open-label, multicentre phase I/II study (DSHNHL-R6)

Stephan Fuhrmann, Maike Nickelsen, Justin Hasenkamp, Andreas Hüttmann, Martin Dreyling, Michael Kiehl, Hans Salwender, Marius Placzek, Reinhard Hilgers, Norbert Schmitz, Bertram Glass

Annals of Hematology · 2025

DOI: 10.1007/s00277-025-06355-5 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Annals of Hematology, 2025. Verfasst von Stephan Fuhrmann und 10 weiteren Autor:innen. Beteiligte Einrichtung: Hämatologie/Onkologie Berlin-Mitte, Berlin, Germany. stephan.fuhrmann@onkologie-berlin-mitte.de. Hauptthemen laut MEDLINE: Salvage Therapy, Antineoplastic Combined Chemotherapy Protocols, Lymphoma, B-Cell. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Celgene GmbH, Amgen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Treatment of relapsed or refractory aggressive B-cell lymphoma (aNHL) is still an unmet medical need. Platinum-containing salvage immunotherapies achieve remission rates of 40-60%. The phase I/II DSHNHL-R6 trial sought to investigate feasibility, safety and efficacy of R-DHAP plus lenalidomide in patients with first or subsequent relapse of aNHL. 33 patients were enrolled in the trial and could be analyzed (ITT). Lenalidomide dose was stepwise increased if no dose-limiting toxicities were observed. Maximum tolerated dose (MTD) for lenalidomide in combination with R-DHAP was 15 mg administered on days 1-7 of each cycle. The overall response rates (ORR; defined as complete, unconfirmed complete or partial remission; using the revised response criteria by CT) and complete response rates (CR) rates were 60.6% and 27.3% for the ITT-population and 81.3% and 50.0% in the patients treated as per protocol (PP). With a median follow-up of 13.9 months, the median OS was 21.2 months and PFS for the ITT and PP-population were 10.7 and 18.9 months respectively. No treatment related deaths were observed. Haematologic adverse events (77% grade 3-4) were common. Combining Lenalidomide with R-DHAP is an effective salvage therapy for patients with aNHL. Prolonged use of lenalidomide lead to more toxicities. (registered at www.clinicaltrialsregister.eu ; EudraCT number: 2009-010824-25; Start Date: 2010-04-12).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Salvage TherapyAntineoplastic Combined Chemotherapy ProtocolsLymphoma, B-CellHumansLenalidomideMaleMiddle AgedFemaleAgedDexamethasoneRituximabAdultCytarabineCisplatinMaximum Tolerated Dose

Stichwörter der Autor:innen

R-DHAPRelapsed/refractory B-cell lymphomaSalvage therapylenalidomide

Substanzen

LenalidomideDexamethasoneRituximabCytarabineCisplatin

Autor:innen und Institutionen

  • Hämatologie/Onkologie Berlin-Mitte, Berlin, Germany. stephan.fuhrmann@onkologie-berlin-mitte.de.
  • Onkologie Lerchenfeld, Hamburg, Germany.
  • Clinic for Hematology and Medical Oncology, University Medicine Göttingen, Georg-August-University, Göttingen, Germany.
  • Universitatsklinikum Essen, Essen, Germany.
  • Department of Medicine III, LMU Hospital, Munich, Germany.
  • Department of Internal Medicine, General Hospital, Frankfurt/Oder, Germany.

Förderung

  • Celgene GmbH
  • Amgen

Zitieren

APA

Fuhrmann, S., Nickelsen, M., Hasenkamp, J., Hüttmann, A., Dreyling, M., Kiehl, M., Salwender, H., Placzek, M., Hilgers, R., Schmitz, N., & Glass, B. (2025). Lenalidomide in combination with rituximab, dexamethasone, high-dose ARA-C and cisplatinum as salvage therapy in refractory or relapsed aggressive B-cell non-hodgkin-lymphoma - an open-label, multicentre phase I/II study (DSHNHL-R6). Annals of Hematology. https://doi.org/10.1007/s00277-025-06355-5

Vancouver

Fuhrmann S, Nickelsen M, Hasenkamp J, Hüttmann A, Dreyling M, Kiehl M, et al. Lenalidomide in combination with rituximab, dexamethasone, high-dose ARA-C and cisplatinum as salvage therapy in refractory or relapsed aggressive B-cell non-hodgkin-lymphoma - an open-label, multicentre phase I/II study (DSHNHL-R6). Annals of Hematology. 2025. doi:10.1007/s00277-025-06355-5

BibTeX
@article{Fuhrmann2025,
  author = {Fuhrmann, Stephan and Nickelsen, Maike and Hasenkamp, Justin and Hüttmann, Andreas and Dreyling, Martin and Kiehl, Michael and Salwender, Hans and Placzek, Marius and Hilgers, Reinhard and Schmitz, Norbert and Glass, Bertram},
  title = {Lenalidomide in combination with rituximab, dexamethasone, high-dose ARA-C and cisplatinum as salvage therapy in refractory or relapsed aggressive B-cell non-hodgkin-lymphoma - an open-label, multicentre phase I/II study (DSHNHL-R6)},
  journal = {Annals of Hematology},
  year = {2025},
  doi = {10.1007/s00277-025-06355-5}
}
Kostenlos starten →